期刊
AMINO ACIDS
卷 50, 期 7, 页码 885-895出版社
SPRINGER WIEN
DOI: 10.1007/s00726-018-2556-0
关键词
Antisera; Elapid; Micrurus; alpha-Neurotoxin; Synthetic gene; Recombinant; Three finger toxins
资金
- Direccion General de Asuntos del Personal Academico (DGAPA-UNAM) [IN203118]
- SEP-CONACyT [240616]
- CONACYT [367094]
The three-fingered toxin family and more precisely short-chain alpha-neurotoxins (also known as Type I alpha-neurotoxins) are crucial in defining the elapid envenomation process, but paradoxically, they are barely neutralized by current elapid snake antivenoms. This work has been focused on the primary structural identity among Type I neurotoxins in order to create a consensus short-chain alpha-neurotoxin with conserved characteristics. A multiple sequence alignment considering the twelve most toxic short-chain alpha-neurotoxins reported from the venoms of the elapid genera Acanthophis, Oxyuranus, Walterinnesia, Naja, Dendroaspis and Micrurus led us to propose a short-chain consensus alpha-neurotoxin, here named ScNtx. The synthetic ScNtx gene was de novo constructed and cloned into the expression vector pQE30 containing a 6His-Tag and an FXa proteolytic cleavage region. Escherichia coli Origami cells transfected with the pQE30/ScNtx vector expressed the recombinant consensus neurotoxin in a soluble form with a yield of 1.5 mg/L of culture medium. The 60-amino acid residue ScNtx contains canonical structural motifs similar to alpha-neurotoxins from African elapids and its LD50 of 3.8 A mu g/mice is similar to the most toxic short-chain alpha-neurotoxins reported from elapid venoms. Furthermore, ScNtx was also able to antagonize muscular, but not neuronal, nicotinic acetylcholine receptors (nAChR). Rabbits immunized with ScNtx were able to immune-recognize short-chain alpha-neurotoxins within whole elapid venoms. Type I neurotoxins are difficult to isolate and purify from natural sources; therefore, the heterologous expression of molecules such ScNtx, bearing crucial motifs and key amino acids, is a step forward to create common immunogens for developing cost-effective antivenoms with a wider spectrum of efficacy, quality and strong therapeutic value.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据